[1] Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine, 2012, 30: 2212-2219.
[2] 贾继东, 李兰娟. 慢性乙型肝炎防治指南(2010 年版).临床肝胆病杂志,2011,27: 113-128.
[3] Chen CJ, Yang HI. Natural history of chronic hepatitis B reveled. J Gastroenterol Hepatol,2011, 26: 628-638.
[4] Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut, 2012, 61: 1754-1764.
[5] European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J hepatol, 2012, 57: 167-185.
[6] 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南 (2015 年版). 中国肝脏病杂志 (电子版), 2015, 7: 1-18.
[7] Menéndez-Arias L, lvarez M, PachecoB. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol,2014, 8: 1-9.
[8] Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2010, 51: 422-430.
[9] Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J hepatol, 2010, 52: 791-799.
[10] 陆志檬,谢青,张大志,等.聚乙二醇干扰素 α- 2a 联合核苷(酸)类似物治疗慢性乙型肝炎研讨会纪要.中华肝脏病杂志,2011,19:228-231.
[11] Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist, 2011, 4: 55-64.
[12] 韩莹,丁惠国.抗病毒治疗乙型肝炎肝硬化的过去,现在和将来.实用肝脏病杂志, 2015, 18: 453-456.
[13] 张晓红, 吴元凯, 曹红, 等. 恩替卡韦治疗乙型肝炎肝硬化并发周围神经病 3 例. 中华肝脏病杂志, 2012, 20: 707-708.
[14] Ehata T, Omata M, Yokosuka O, et al. Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection. J Clin Invest, 1992, 89: 332.
[15] Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology, 2007, 45: 1056-1075.
[16] Lin F,Young HA. Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev, 2014, 25: 369-376.
[17] ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. Hepatology, 2006, 44: 721-727.
[18] Sun J, Hou JL, Xie Q, et al. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.Aliment Pharmacol Ther,2011, 34: 424-431.
[19] Seo Y, Yano Y. Short-and long-term outcome of interferon therapy for chronic hepatitis B infection. World J Gastroenterol,2014, 20: 13284.
[20] Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin α1. Expert Opin Biol Ther,2009, 9: 593-608.
[21] 顾锡炳.慢性重症肝炎患者T细胞亚群的变化.肝脏,2000,6:210-211.
[22] 赵艳娟, 高歌. 干扰素 α2b 与苦参素, 胸腺肽 α1 联合序贯治疗慢性乙型肝炎的实验研究. 临床肝胆病杂志, 2005, 21: 341-342.
[23] Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med,2004, 351: 1206-1217.
[24] Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.Lancet, 2005, 365: 123-129.
[25] Liu CJ, Wang CC, Yang SS, et al. 758 Entecavir plus Peginterferon alfa-2a vs. Entecavir alone in the treatment of Hepatitis B e antigen-positive chronic hepatitis B:An interim roport. J Hepatol, 2013, 58: S308.
[26] Marcellin P, Wursthorn K, Wedemeyer H, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J hepatol, 2015, 62: 41-47.
[27] Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.Hepatology, 2011, 53: 763-773.
[28] Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology, 2015, 61: 1512-1522.
[29] Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med, 2005, 352: 2682-2695.
[30] 刘洁, 漆俊, 胥富波, 等. 干扰素, 核苷 (酸) 类似物单独及二者序贯治疗 HBeAg 阳性慢性乙型肝炎的比较. 中国肝脏病杂志 (电子版), 2015, 7: 59-63.
[31] 杨龙, 杨阳, 陈志勇, 等. 聚乙二醇干扰素 α-2a 治疗多种核苷 (酸) 类药物耐药慢性乙型肝炎的疗效. 实用医学杂志, 2014, 30: 503-504.
[32] Xie Q, Zhou H, Bai X, et al. A randomized, open-label clinical study of combined pegylated Interferon alfa-2a (40KD) and entecavir treatment for hepatitis B “e” antigen-positive chronic hepatitis B. Clin Infect Dis, 2014: ciu702.
[33] 程丹, 刘文涛, 黄新造. 恩替卡韦联合 α1 胸腺肽治疗 HBeAg 阳性慢性乙型肝炎疗效及安全性分析. 实用肝脏病杂志, 2012, 15: 350-351.
[34] 侯彦亭,孙宗云,魏连军.慢性乙型肝炎患者核苷 (酸) 类似物停药后胸腺肽α1序贯治疗的疗效观察.安徽医药,2013,17: 259-261. |
